In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. 3 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche subsidiary Genentech for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. 3 December 2024
Biotechnology
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. 3 December 2024
Pharmaceutical
Suzhou’s Atom Therapeutics, has inked a deal with China Medical System (CMS) to commercialize lingdolinurad (ABP-671) in China, Hong Kong, and Macao. 3 December 2024
Biotechnology
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
Biotechnology
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeier as its chief business officer (CBO). 3 December 2024
Biotechnology
Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European biopharmaceutical companies reporting a 325% surge ($921 million) from 2023 to 2024 year-to-date (YTD), compared to a 90.5% rise ($256 million) in the USA. 3 December 2024
Biotechnology
China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate (fruquintinib) and Tyvyt (sintilimab). 3 December 2024
Pharmaceutical
The Advanced Research Projects Agency for Health (ARPA-H), an agency established in 2022 in the USA, has launched a new Advancing Clinical Trial Readiness (ACTR) initiative. 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Biotechnology
New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for patients severely impacted by migraine. 3 December 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics announced that it has strengthened the company’s leadership and executive team with two new appointments. 3 December 2024
Pharmaceutical
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
Biotechnology
French biotech Ipsen has entered an exclusive global licensing agreement with Biomunex Pharmaceuticals to develop BMX-502, a first-in-class T cell engager. 3 December 2024
Pharmaceutical
Swedish pharma Orexo and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for the former firm to commercialize the digital mental health program for depression, Deprexis, in the USA. 2 December 2024
Biotechnology
Netherlands and USA-based Merus has inked an exclusive licensing accord with privately-held Partner Therapeutics (PTx), for the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the USA. 2 December 2024
Pharmaceutical
Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III PANOVA-3 trial, demonstrating a statistically-significant improvement in median overall survival (mOS) versus control. 2 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze